Synopsis:
Godavari Biorefineries Ltd secured a European patent for compounds targeting cancer stem cells, detailing their structures, synthesis, and biological activity. This R&D milestone underscores the company’s innovation in anti-cancer therapeutics and growth potential.
This company is a manufacturer of Bio-based Chemicals and Ethanol is now in the spotlight after it hit the 10% upper circuit because its European patent has been granted.
With market capitalization of Rs. 1,348 cr, the shares of Godavari Biorefineries Ltd are currently trading at Rs. 263 per share, locked at 10% upper circuit in today’s market session, from its previous close of Rs. 239.10 per share.
News
On October 16, 2025, Godavari Biorefineries Limited announced that its European patent for the Anti-Cancer Research segment, titled “Compounds for the Inhibition of Unregulated Cell Growth,” has been granted.
The patent covers novel chemical compounds that inhibit unregulated cell growth, specifically targeting cancer stem cells, and includes details on their chemical structures, synthesis processes, and biological activity.
These compounds have demonstrated strong potential in treating cancers such as breast and prostate cancer, marking a significant R&D milestone for the company.
The disclosure, made under SEBI Listing Regulations, highlights Godavari Biorefineries’ commitment to innovative pharmaceutical research, strengthens its intellectual property portfolio, and could open avenues for future commercialization in oncology therapeutics.
About the company
Godavari Biorefineries Ltd is an India-based company specializing in biofuels, chemicals, and renewable energy solutions, with a strong focus on research-driven innovations in pharmaceuticals and biotechnology. The company engages in the production of ethanol, specialty chemicals, and anti-cancer research compounds, combining sustainable industrial practices with advanced R&D to strengthen its presence in domestic and international markets.
Sales of the company declined from Rs. 580 cr in Q4FY25 to Rs. 533 cr in Q1FY26. Operating profit significantly fell to Rs. 6 cr from Rs. 112 cr. Net profit also decreased from Rs. 72 cr to a loss of Rs. 16 cr during the same period.
Written by Manideep Appana
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post Chemical stock hits 10% upper circuit after receiving patent for compounds targeting cancer stem cells appeared first on Trade Brains.